Ocera Therapeutics Receives a Buy from H.C. Wainwright

By Ryan Adsit

In a report issued on March 10, Ed Arce from H.C. Wainwright reiterated a Buy rating on Ocera Therapeutics (NASDAQ: OCRX), with a price target of $4. The company’s shares closed last Friday at $1.40.

According to TipRanks.com, Arce is a top 100 analyst with an average return of 31.2% and a 50.0% success rate. Arce covers the Healthcare sector, focusing on stocks such as Neptune Technologies & Bioresources Inc, Aviragen Therapeutics Inc, and Sucampo Pharmaceuticals.

Currently, the analyst consensus on Ocera Therapeutics is Moderate Buy and the average price target is $3.50, representing a 150.0% upside.

In a report issued on March 9, Aegis Capital also reiterated a Buy rating on the stock with a $3 price target.

Based on Ocera Therapeutics’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $512K and GAAP net loss of $5.15 million. In comparison, last year the company earned revenue of $24K and had a GAAP net loss of $7.08 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in development and commercialization of OCR-002 (ornithine phenylacetate0 in intravenous and oral formulations. The company was founded by Wu Xiaoyun, John C. Kappes, and Eckard Weber on January 12, 1998 and is headquartered in Palo Alto, CA.